Albumin Or Derivative Affecting Or Utilizing Patents (Class 514/15.2)
-
Publication number: 20120238998Abstract: A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.Type: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Inventors: Peter Kiessling, Dietrich BOSSE, Johanness Zeiss, Gaston DIDERRICH
-
Publication number: 20120220530Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: November 1, 2010Publication date: August 30, 2012Applicant: Novozymes Biopharma DK A/SInventors: Andrew Plumridge, Darrell Sleep, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20120219589Abstract: The invention relates to percutaneous administration of drugs and vaccines in form of solid penetrating needles, “injectable needles”, comprising a polymeric matrix resulting from the polymerization of a polymerizable paste or mixture. The injectable needles are hard enough to penetrate the skin and can be administered percutaneously by simple pusher or injector delivery devices. The manufacturing procedure of the injectable needles allows for the incorporation of the drug as preformulated stable microparticles and incorporation of modifying agents to modulate stiffness, solubility and drug release. Drugs formulated in these injectable needles offer a safe, simple and effective alternative to conventional percutaneous drug delivery systems based on hypodermic needles and syringes that require refrigerated storage and reconstitution prior to administration.Type: ApplicationFiled: October 8, 2010Publication date: August 30, 2012Applicant: AZUREBIO ,S.L.Inventors: Arcadio García De Castro Andrews, Raúl García Carrodeaguas, Niuris Acosta Contreras
-
Patent number: 8252747Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.Type: GrantFiled: July 27, 2009Date of Patent: August 28, 2012Inventors: Johan Lowinger, Bruno Lowinger, Frank DeLustro, David Cox, David A. Browdie
-
Publication number: 20120195883Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: April 17, 2012Publication date: August 2, 2012Applicant: VENTRIA BIOSCIENCEInventors: NING HUANG, RAYMOND L. RODRIQUEZ, FRANK E. HAGIE, DAVID M. STALKER
-
Publication number: 20120189704Abstract: A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.Type: ApplicationFiled: April 3, 2012Publication date: July 26, 2012Applicant: CHI2GEL LTD.Inventors: Noah Ben-Shalom, Zvi Nevo, Abraham Patchornik, Dror Robinson
-
Publication number: 20120189668Abstract: Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair.Type: ApplicationFiled: January 26, 2012Publication date: July 26, 2012Inventor: Stanley William Whitson
-
Publication number: 20120183541Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
-
Publication number: 20120178694Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.Type: ApplicationFiled: May 3, 2010Publication date: July 12, 2012Inventors: John D. Lambris, Hongchang Qu
-
Publication number: 20120177644Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.Type: ApplicationFiled: July 13, 2010Publication date: July 12, 2012Applicants: THE SCRIPPS RESEARCH INSTITUTE, IRM LLCInventors: Peter G. Schultz, Kristen Johnson, Lori Jennings
-
Publication number: 20120177610Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: May 24, 2011Publication date: July 12, 2012Inventor: Kieu Hoang
-
Publication number: 20120164183Abstract: The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin.Type: ApplicationFiled: November 23, 2008Publication date: June 28, 2012Inventors: Lionel C. Sevrain, Sylvie Y. Verdier- Sevrain
-
Publication number: 20120164087Abstract: Dermatological compositions and method for treating psoriasis, eczema, acne and like skin conditions for sanitization pharmaceutical compounding and protection of the skin from extreme environmental conditions are provided which contain serum albumin in an amount effective to treat, reduce the symptoms and improve the appearance of affected skin due to psoriasis, eczema, and acne and like conditions, enhance the delivery performance or stability of pharmaceutical compounding bases, protect the skin from the environment and premature aging, and to lubricate and/or promote the healing of eye after surgical or accidental trauma, when combined with a suitable topical ointment, antibacterial or dermatological agent, pharmaceutical compounding ointment or bases, vehicle, carrier or excipient. The albumin compositions may be in any suitable form for treating skin, such as a cream, oil, lotion, gel, gel-based ointment, and the like.Type: ApplicationFiled: April 26, 2010Publication date: June 28, 2012Inventor: Daniel C. Carter
-
Publication number: 20120164072Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.Type: ApplicationFiled: May 4, 2010Publication date: June 28, 2012Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
-
Publication number: 20120164071Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 28, 2012Inventors: Philip E. Thorpe, M. Melina Soares, Jin He
-
Publication number: 20120148670Abstract: A polymer capsule manufactured by polymerizing a compound represented by Formula 1, or polymerizing the compound of Formula 1 and a compound of Formula 2, wherein a detailed structure of the compounds of Formulae 1 and 2 is presented in the detailed description.Type: ApplicationFiled: August 11, 2010Publication date: June 14, 2012Applicant: POSTECH ACADEMAY-INDUSTRY FOUNDATIONInventors: Ki moon Kim, Jiyeong Lee, Dongwoo Kim, Eunju Kim, Hyuntae Jung
-
Patent number: 8198243Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: GrantFiled: October 12, 2011Date of Patent: June 12, 2012Inventor: Cuthbert O. Simpkins
-
Publication number: 20120141415Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: June 7, 2012Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20120128763Abstract: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.Type: ApplicationFiled: February 2, 2012Publication date: May 24, 2012Inventor: Steven Maskin
-
Patent number: 8183209Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: September 28, 2011Date of Patent: May 22, 2012Assignee: DMI Biosciences, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120101041Abstract: Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic dendrimer which comprises a hydrophilic linear polymer as the core and polyester dendrons attached to both terminals of the linear polymer and in which cationic groups are bonded to the surfaces of the dendrons, said cationic groups being selected from the group consisting of guanidine group, thiourea group, and isothiourea group; a material for a hydrogel, which comprises the polyionic dendrimer and clay; and a hydrogel prepared using the material.Type: ApplicationFiled: June 28, 2010Publication date: April 26, 2012Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Justin Mynar, Takuzo Aida
-
Publication number: 20120093798Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: August 19, 2008Publication date: April 19, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Publication number: 20120082715Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: ApplicationFiled: September 2, 2011Publication date: April 5, 2012Inventor: David Needham
-
Publication number: 20120076862Abstract: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”).Type: ApplicationFiled: March 28, 2011Publication date: March 29, 2012Inventors: Neil P. Desai, Patrick Soon-Shiong
-
Patent number: 8143026Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: August 3, 2009Date of Patent: March 27, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben, Paul A. Moore, Jason B. Bock, David LaFleur
-
Patent number: 8137558Abstract: A method for producing biofuels is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, extracting neutral lipids from the algal biomass, and esterifying the neutral lipids with a catalyst in the presence of an alcohol. The method also includes separating a water soluble fraction comprising glycerin from a water insoluble fraction comprising fuel esters and distilling the fuel esters under vacuum to obtain a C16 or shorter fuel esters fraction, a C16 or longer fuel ester fraction, and a residue comprising carotenoids and omega-3 fatty acids. The method further includes hydrogenating and deoxygenating at least one of (i) the C16 or shorter fuel esters to obtain a jet fuel blend stock and (ii) the C16 or longer fuel esters to obtain a diesel blend stock.Type: GrantFiled: September 30, 2011Date of Patent: March 20, 2012Assignee: Heliae Development, LLCInventor: Aniket Kale
-
Publication number: 20120058100Abstract: Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: November 11, 2011Publication date: March 8, 2012Inventors: V. Prasad Shastri, Jay C. Sy
-
Publication number: 20120046231Abstract: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.Type: ApplicationFiled: August 23, 2011Publication date: February 23, 2012Inventors: Andre Francis Palmer, Pedro Cabrales
-
Publication number: 20120034277Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Inventor: Cuthbert O. SIMPKINS
-
Publication number: 20120027690Abstract: The present document relates to a manufacturing method for pH-sensitive graft polymer micelles and a polymer micelle-type pharmaceutical composition containing the graft copolymer. The pH-sensitive graft copolymer micelles are usable as various markers and contrast agents for various molecular images for the diagnosis and treatment of diseases and a carrier for delivery of various medicines according to disease. The pH-sensitive graft copolymer forms micelles that can be used in target-oriented diagnosis and medicine release according to changes in the pH of a body. The polymer micelles are provided by inducing a graft copolymer of poly(?-amino ester) compounds which has a solubility in water depending on pH but is incapable of forming the micelles due to a self-assembly phenomenon, and hydrophilic poly(ethylene glycol) compounds.Type: ApplicationFiled: April 9, 2010Publication date: February 2, 2012Applicant: Research & Business Foundation Sungkyunkwan UniversityInventors: Doo Sung Lee, Min Sang Kim, Bong Sup Kim
-
Publication number: 20120030779Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.Type: ApplicationFiled: January 18, 2008Publication date: February 2, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDTIONInventors: Ivor J. Benjamin, Namakkal S. Rajasekaran, Thomas P. Kennedy
-
Publication number: 20120024743Abstract: The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.Type: ApplicationFiled: February 5, 2010Publication date: February 2, 2012Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulasik, Patrik Fazekas
-
Publication number: 20120020959Abstract: The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy.Type: ApplicationFiled: June 3, 2011Publication date: January 26, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Xiping Liu, Neil Desai
-
Publication number: 20120010144Abstract: This composition comprises a polyethylene glycol-albumin composition having at least one protected thiol region wherein the composition comprises PEG-AlbCys34 with Cys-34 preserved as a thiol. The albumin is linked to medications such as, antioxidants with a reduced sulfhydryl group through the Cys 34 residing on the albumin. The compositions are useful in treating patients.Type: ApplicationFiled: April 2, 2010Publication date: January 12, 2012Inventors: Ragheb Assaly, John David Digman, Joseph I Shapiro
-
Publication number: 20120004177Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: March 1, 2011Publication date: January 5, 2012Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Publication number: 20110293594Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
-
Publication number: 20110286937Abstract: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed.Type: ApplicationFiled: February 18, 2009Publication date: November 24, 2011Applicants: GIFU UNIVERSITY, KATAYAMA CHEMICAL INDUSTRIES CO., LTD.Inventors: Makoto Kiso, Hideharu Ishida, Taiji Yamashita, Koichi Igarashi, Masahiko Hirai
-
Patent number: 8063020Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: GrantFiled: December 16, 2008Date of Patent: November 22, 2011Inventor: Cuthbert O. Simpkins
-
Publication number: 20110280864Abstract: The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle.Type: ApplicationFiled: November 10, 2009Publication date: November 17, 2011Applicant: Board of Regents, The University of Texas SystemInventors: Keith P. Johnston, Maria Andrea Mazuski, Joshua Engstrom, Miguel Angelo Rodrigues
-
Publication number: 20110281800Abstract: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention.Type: ApplicationFiled: May 22, 2009Publication date: November 17, 2011Inventor: David James Ballance
-
Publication number: 20110263502Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.Type: ApplicationFiled: June 26, 2009Publication date: October 27, 2011Inventors: Daniel V. Santi, Gary W. Ashley, Brian Hearn
-
Patent number: 8039432Abstract: The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.Type: GrantFiled: November 9, 2006Date of Patent: October 18, 2011Assignee: Conjuchem, LLCInventors: Dominique P. Bridon, Jean-Paul Castaigne, Karen Thibaudeau
-
Publication number: 20110250297Abstract: Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier.Type: ApplicationFiled: September 25, 2009Publication date: October 13, 2011Inventors: Bryan T. Oronsky, Peter Langecker
-
Publication number: 20110250240Abstract: A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range.Type: ApplicationFiled: April 13, 2011Publication date: October 13, 2011Inventor: Albert Crum
-
Publication number: 20110251566Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.Type: ApplicationFiled: April 9, 2010Publication date: October 13, 2011Inventors: DMITRY ZIMNITSKY, Jenny Finkbiner
-
Publication number: 20110245177Abstract: A method for the prevention or treatment of an eye disease, which includes topically applying to a patient in need of the treatment an aqueous ophthalmic composition which includes N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine, in combination with an amount of a cellulose compound or a pharmacologically acceptable salt which is effective to increase intraocular absorption of N-acetylcarnosine or L-carnosine or a derivative of L-carnosine, such as anserine or balenine, in the aqueous humor. A hydrophilic hydrogel contact lens and an ocular polymer insert for topical application of an ophthalmic composition to the eyes of a patient is also disclosed, with the lens or insert containing N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine.Type: ApplicationFiled: July 19, 2010Publication date: October 6, 2011Inventor: Mark A. BABIZHAYEV
-
Publication number: 20110230411Abstract: Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue.Type: ApplicationFiled: January 31, 2008Publication date: September 22, 2011Applicant: ZVI NEVOInventors: Eyal Zussman, David Simhon, Shmuel Chervinsky, Abraham Katzir, Zvi Nevo, Yael Dror
-
Publication number: 20110223208Abstract: The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations and methods of making and using them.Type: ApplicationFiled: March 9, 2011Publication date: September 15, 2011Inventors: Beth Hill, Weiguo Dai